Simponi, a subcutaneously administered anti-tumor necrosis factor therapy, has shown to induce clinical remission in ulcerative colitis patients.
More Articles on Gastroenterology:
PENTAX Launches Video Processor With PENTAX i-SCAN
SAGES Appoints Dr. Gerald Fried President
AGA Receives $1.5M Research Grant From Takeda Pharmaceuticals
